<DOC>
	<DOCNO>NCT00026429</DOCNO>
	<brief_summary>RATIONALE : Biological therapy denileukin diftitox may able deliver cancer-killing substance directly non-Hodgkin 's lymphoma cell . PURPOSE : Phase II trial study effectiveness denileukin diftitox treat patient non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Denileukin Diftitox Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy denileukin diftitox patient stag I-IV low- intermediate-grade B-cell non-Hodgkin 's lymphoma . II . Determine safety drug patient . OUTLINE : This multicenter study . Patients receive denileukin diftitox IV 30-60 minute day 1-5 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients may receive 2 additional course achieve complete response . Patients follow every 3 month progress 2 year date termination . PROJECTED ACCRUAL : A total 58 patient ( 29 low-grade non-Hodgkin 's lymphoma ( NHL ) 29 intermediate-grade NHL ) accrue study within 12 month . The study may stop accrual 20 patient ( 10 low-grade NHL 10 intermediate-grade NHL ) observe response rate le 1 10 stratum .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm lowgrade Bcell nonHodgkin 's lymphoma ( NHL ) Working Formulation classification : Small lymphocytic lymphoma Follicular lymphoma ( small cleave mixed small large cell ) REAL classification : Bcell chronic lymphocytic leukemia/small lymphocytic Lymphoplasmacytoid Marginal zone/MALT Follicular small mix small large cell OR Histologically confirm intermediategrade Bcell NHL Working Formulation classification : Follicular large cell Diffuse small cleave cell Diffuse mix small large cell Diffuse large cell REAL classification : Mantle cell Diffuse small cell Marginal zone/MALT Large Bcell Lymphoplasmacytoid Stage I , II , III , IV disease No cutaneous Tcell lymphoma Tcell NHL Bidimensionally measurable disease Unidimensionally measurable disease allow mediastinal lymphoma outside previously irradiate field evidence progression Received prior monoclonal antibody therapy OR ineligible monoclonal antibody therapy A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,000/mm3 Platelet count least 50,000/mm3 Hemoglobin least 8 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 1.5 time ULN Albumin least 3.0 g/dL No chronic hepatitis Renal : Creatinine le 1.8 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease No poorly control hypertension Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No serious concurrent illness active infection require parenteral antibiotic would preclude study No known hypersensitivity study drug component , include diphtheria toxin , interleukin2 , excipients No malignancy within past 5 year except resect basal squamous cell skin cancer carcinoma situ cervix ( prostate cancer situ breast cancer situ within past 5 year allow patient complete remission active disease , stable tumor marker least 3 month , life expectancy least 2 year ) PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Prior bone marrow transplantation allow No prior denileukin diftitox DAB486 IL2 No concurrent immunotherapy Chemotherapy : No concurrent chemotherapy Endocrine therapy : No concurrent hormonal anticancer therapy Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy No prior radiotherapy sole site disease unless evidence progression No concurrent radiotherapy Surgery : Not specify Other : At least 1 month since prior investigational agent No concurrent experimental medication , include approve drug test investigational setting</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2002</verification_date>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
</DOC>